

Title (en)

METHODS AND COMPOSITIONS FOR DECTIN-2 STIMULATION AND CANCER IMMUNOTHERAPY

Title (de)

VERFAHREN UND ZUSAMMENSETZUNGEN ZUR DECTIN-2-STIMULATION UND KREBSIMMUNTHERAPIE

Title (fr)

PROCÉDÉS ET COMPOSITIONS POUR LA STIMULATION DE LA DECTINE 2 ET L'IMMUNOTHÉRAPIE CONTRE LE CANCER

Publication

**EP 3645043 A4 20210407 (EN)**

Application

**EP 18824402 A 20180627**

Priority

- US 201762526266 P 20170628
- US 2018039868 W 20180627

Abstract (en)

[origin: WO2019006038A1] Provided are methods and compositions for treating an individual with cancer or infectious disease. Multivalent Dectin-2 stimulating agents are provided that include: (a) an agent that binds to Dectin-2 and stimulates Dectin-2 signaling; and (b) an antibody and/or an immunomodulatory agent, wherein (a) and (b) are conjugated to one another. In some cases, (a) is a mannobiose glycopolyptide that binds to Dectin-2. In some cases (b) is a stimulatory ligand for a TLR (e.g., TLR7, TLR8, TLR7/8, TLR2, and the like). Methods of treating an individual with cancer and/or an infectious disease can include administering to the individual an effective amount of a Dectin-2 stimulating composition. In some cases, the Dectin-2 stimulating composition comprises a Dectin-2 stimulating glycopolymer. In some cases the Dectin-2 stimulating composition comprises a multivalent Dectin-2 stimulating agent.

IPC 8 full level

**A61K 39/395** (2006.01); **C07K 16/28** (2006.01); **C12N 5/078** (2010.01); **C12N 5/0783** (2010.01); **C12N 5/0784** (2010.01)

CPC (source: EP KR US)

**A61K 38/00** (2013.01 - EP); **A61K 39/00117** (2018.08 - EP US); **A61K 39/39541** (2013.01 - EP US); **A61K 47/55** (2017.08 - EP KR); **A61K 47/61** (2017.08 - EP KR); **A61K 47/62** (2017.08 - EP); **A61K 47/646** (2017.08 - EP KR); **A61K 47/6803** (2017.08 - EP US); **A61K 47/6807** (2017.08 - EP KR); **A61K 47/6811** (2017.08 - EP KR); **A61K 47/6849** (2017.08 - EP KR); **A61K 47/6851** (2017.08 - EP KR); **A61P 31/00** (2018.01 - KR); **A61P 35/00** (2018.01 - KR US); **C07K 16/243** (2013.01 - EP KR); **C07K 16/2818** (2013.01 - EP KR); **C07K 16/2851** (2013.01 - EP KR US); **C07K 16/2878** (2013.01 - EP KR US); **C07K 16/30** (2013.01 - EP KR); **A61K 2039/505** (2013.01 - EP); **A61K 2039/507** (2013.01 - EP KR US); **A61K 2300/00** (2013.01 - KR); **C07K 2317/75** (2013.01 - EP KR); **C07K 2317/76** (2013.01 - EP KR)

C-Set (source: EP)

**A61K 39/39541 + A61K 2300/00**

Citation (search report)

- [XY] WO 2013067597 A1 20130516 - ASCEND BIOPHARMACEUTICALS PTY LTD [AU]
- [Y] WO 2015187637 A1 20151210 - BAYLOR RES INST [US]
- [Y] WO 2016032009 A1 20160303 - UNIV KYUSHU NAT UNIV CORP [JP]
- [Y] UPCHURCH KATHERINE C ET AL: "Preclinical Assessment of the Effectiveness of alpha-Dectin-1-Pam3 Conjugate in Controlling T(H)2 Responses", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, & ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-ALLERGY-ASTHMA-AND-IMMUNOLOGY (AAAAI); HOUSTON, TX, USA; FEBRUARY 20 -24, 2015, vol. 135, no. 2, Suppl. S, 1 February 2015 (2015-02-01), pages AB101, XP002776641
- [Y] ISHIKAWA TETSUAKI ET AL: "Identification of Distinct Ligands for the C-type Lectin Receptors Mincle and Dectin-2 in the Pathogenic FungusMalassezia", CELL HOST & MICROBE, ELSEVIER, NL, vol. 13, no. 4, 17 April 2013 (2013-04-17), pages 477 - 488, XP028582651, ISSN: 1931-3128, DOI: 10.1016/J.CHEM.2013.03.008
- [Y] SANCHO D ET AL: "Signaling by Myeloid C-Type Lectin Receptors in Immunity and Homeostasis", ANNUAL REVIEW OF IMMUNOLOGY, ANNUAL REVIEWS INC, vol. 30, 1 January 2012 (2012-01-01), pages 491 - 529, XP002693450, ISSN: 0732-0582, [retrieved on 20120106], DOI: 10.1146/ANNUREV.IMMUNOL-031210-101352
- [Y] VASSO APOSTOLOPOULOS ET AL: "Targeting Antigens to Dendritic Cell Receptors for Vaccine Development", JOURNAL OF DRUG DELIVERY, vol. 23, no. 7, 1 January 2013 (2013-01-01), pages 1739 - 22, XP055197328, ISSN: 2090-3014, DOI: 10.1155/2013/869718
- See also references of WO 2019006038A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

**WO 2019006038 A1 20190103**; AU 2018290880 A1 20200116; CA 3067146 A1 20190103; CN 111032087 A 20200417; EP 3645043 A1 20200506; EP 3645043 A4 20210407; JP 2020526482 A 20200831; KR 20200021095 A 20200227; US 2020140556 A1 20200507

DOCDB simple family (application)

**US 2018039868 W 20180627**; AU 2018290880 A 20180627; CA 3067146 A 20180627; CN 201880055732 A 20180627; EP 18824402 A 20180627; JP 2019569361 A 20180627; KR 20207002469 A 20180627; US 201816626845 A 20180627